iBio
Estee Silk has extensive work experience in the financial industry. Estee currently serves as the Corporate Controller at iBio, Inc. since May 2021. Prior to their current role, they worked at Teva Pharmaceuticals for over 20 years, starting as a Senior Director of Financial Reporting in November 2000 and transitioning into various roles during their tenure. Before joining Teva Pharmaceuticals, Estee worked as a Senior Accountant at Sanofi from October 1998 to August 2000. Estee began their career at KPMG as an Auditor from October 1995 to October 1998.
Estee Silk attended Drexel University from 1990 to 1995, where they earned a Bachelor of Science (BS) degree in Accounting. Estee has also obtained a Certified Public Accountant (CPA) certification from the State of Pennsylvania, although the specific month and year of obtaining the certification are not provided.
This person is not in any offices
iBio
iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2. iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming™ and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce COVID-19 biologics.